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Entrectinib in children and young adults with solid or
primary CNS tumors harboring NTRK, ROS1, or ALK
aberrations (STARTRK-NG)

Desai et al. Entrectinib in children and young adults

• Entrectinib has activity in pediatric solid tumors with NTRK or ROS1 fusions.
• The MTD for pediatric patients was identified as 550 mg/m2 daily (F1 formulation).
• Based on PK modeling, the pediatric RP2D is 300 mg/m2 daily (F06 formulation).

Importance of the Study
Entrectinib is a potent TRKA/B/C, ROS1, and ALK tyrosine kinase inhibitor that penetrates the blood-brain barrier. Studies in adults demonstrate activity in TRK inhibitor
treatment-naïve patients with NTRK fusion-positive solid
tumors and ROS1 inhibitor treatment-naïve patients with
ROS1 fusion-positive non–small-cell lung cancer, including patients with central nervous system metastases.
Specific evaluation of entrectinib in pediatric patients is
necessary to determine the appropriate dose and whether

Chromosomal translocations and gene rearrangements
resulting in constitutive kinase activation promote carcinogenesis through aberrant signaling via cellular growth
pathways.1 Rearrangements in neurotrophic tyrosine receptor kinase (NTRK), ROS proto-oncogene 1 (ROS1),
and anaplastic lymphoma kinase (ALK) genes result
in fusion proteins that are oncogenic drivers of some
childhood cancers.2 NTRK1, NTRK2, or NTRK3 fusions,
encoding TRKA, TRKB, and TRKC, respectively, occur at
high frequency (>90%) in some rare pediatric tumors,
including infantile fibrosarcoma (IF), congenital mesoblastic nephroma, and secretory breast carcinoma; at

similar safety and efficacy can be achieved in this population. The STARTRK-NG study, including 35 patients aged
<12 years, demonstrates that entrectinib is an important
therapeutic option for pediatric patients with NTRK or
ROS1 fusion-positive intracranial and extracranial solid
tumors. Further investigations are ongoing to assess an
age-appropriate formulation, determine the optimal duration of therapy, and monitor for resistance and long-term
side effects of entrectinib in pediatric patients.

low frequency (5%-25%) in a subset of pediatric gliomas,
gastrointestinal stromal tumors, melanoma, and papillary thyroid cancer; and rarely (<5%) in most common
tumors including adenocarcinoma, gastrointestinal carcinoma, acute leukemia, or soft tissue sarcoma including
inflammatory myofibroblastic tumors (IMT).3–5 ROS1 rearrangements have mainly been described in pediatric
high-grade gliomas (HGG),6 and a subset of ALK-negative
IMTs.7 ALK rearrangements occur in non–small-cell lung
cancer (NSCLC), anaplastic large-cell lymphoma, renal,
breast, and colorectal carcinomas,8 pediatric HGG,6 and
IMTs.7 ALK gain-of-function mutations are seen in ~14% of
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Abstract
Background. Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of
adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusionpositive non–small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investigating the recommended phase 2 dose (RP2D) and activity of entrectinib in pediatric patients with solid tumors including
primary central nervous system tumors.
Methods. STARTRK-NG (NCT02650401) is a phase 1/2 trial. Phase 1, dose-escalation of oral, once-daily
entrectinib, enrolled patients aged <22 years with solid tumors with/without target NTRK1/2/3, ROS1, or ALK
fusions. Phase 2, basket trial at the RP2D, enrolled patients with intracranial or extracranial solid tumors
harboring target fusions or neuroblastoma. Primary endpoints: phase 1, RP2D based on toxicity; phase 2,
objective response rate (ORR) in patients harboring target fusions. Safety-evaluable patients: ≥1 dose of
entrectinib; response-evaluable patients: measurable/evaluable baseline disease and ≥1 dose at RP2D.
Results. At data cutoff, 43 patients, median age of 7 years, were response-evaluable. In phase 1, 4 patients
experienced dose-limiting toxicities. The most common treatment-related adverse event was weight gain
(48.8%). Nine patients experienced bone fractures (20.9%). In patients with fusion-positive tumors, ORR was
57.7% (95% CI 36.9-76.7), median duration of response was not reached, and median (interquartile range)
duration of treatment was 10.6 months (4.2-18.4).
Conclusions. Entrectinib resulted in rapid and durable responses in pediatric patients with solid tumors harboring NTRK1/2/3 or ROS1 fusions.
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patients with newly diagnosed high-risk neuroblastoma.9
TRKA/C and TRKB are overexpressed in non-high-risk and
high-risk neuroblastoma, respectively.10
Entrectinib is a potent, central nervous system (CNS)penetrant inhibitor of TRKA/B/C, ROS1, and ALK.11
Entrectinib was first approved in the United States (2019)
for adults and children (≥12 years old) with advanced
NTRK fusion-positive solid tumors and adults with
ROS1 fusion-positive NSCLC who are TRK- or ROS1 inhibitor treatment-naïve and was subsequently approved
in the EU (2020).12,13 The recommended dose in adults is
600 mg daily. Objective response rates (ORR; 95% confidence interval [CI]) were 63.5% (n = 47/74; 51.5-74.4) and
67.1% (n = 108/161; 59.3-74.3) in adults with NTRK and
ROS1 fusion-positive tumors, respectively, including
a total of 75 patients with baseline intracranial disease
(investigator-assessed).14,15
Based on the mechanism of action, safety profile, responses in adults, and the presence of NTRK1/2/3, ROS1,
and ALK alterations in pediatric cancers, the STARTRK-NG
clinical trial of entrectinib in pediatric patients
(NCT02650401) was initiated (2016). Here, we report the determination of the recommended phase 2 dose (RP2D) and
efficacy and safety results from the phase 2 expansion as
of September 2020.

Methods
Study Design and Participants

  
Patients screened for eligibility
(n = 49)
Excluded (n = 6)
Enrolled (n = 43)
Phase 1 (dose escalation;
cohort A)
(n = 16)

Phase 2 (dose expansion)a,b
(n = 27)

Dose: 250 mg/m 2
(F1) (n = 3)

Dose: 400 mg/m 2
(F1) (n = 3)

Dose: 550 mg/m2
(F1) (n = 7)

Dose: 750 mg/m2
(F1) (n = 3)

Received entrectinib
250 mg/m2 (n = 3)

Received entrectinib
400 mg/m2 (n = 3)

Received entrectinib
550 mg/m2 (n = 7)

Received entrectinib
750 mg/m2 (n = 3)

Included in analysis
(n = 3)

Included in analysis
(n = 3)

Included in analysis
(n = 7)

Included in analysis
(n = 3)

Discontinued treatment
(n = 3)

Discontinued treatment
(n = 3)

Discontinued treatment
(n = 7)

Discontinued treatment
(n = 3)

Progressive disease (n = 5)
Withdrawal of consent (n = 2)

Progressive disease (n = 2)
Adverse event (n = 1)

Remaining in study
(n = 2)

Remaining in study
(n = 1)

In follow-up (n = 2)

In follow-up (n = 1)

Progressive disease (n = 3)

Progressive disease (n = 3)

Remaining in study
(n = 0)

Remaining in study
(n = 0)

Cohort B
Primary CNS tumor
with NTRK or ROS1
gene fusion
Dose: 550 mg/m2
(F1) or 300 mg/m2
(F06) (n = 11)
Received entrectinib
550 mg/m2 (F1) or
300 mg/m2 (F06)
(n = 11)

Included in analysis
(n = 11)
Discontinued treatment
(n = 5)
Progressive disease (n = 3)
Adverse event (n = 2)

Remaining in study
(n = 8)
On study treatment (n = 6)
In follow-up (n = 2)

This cohort is open for
continued enrollment

Cohort C
Neuroblastoma
Dose: 550 mg/m2
(F1) (n = 3)

Received entrectinib
550 mg/m2 (n = 3)

Included in analysis
(n = 3)
Discontinued treatment
(n = 3)
Progressive disease (n = 3)

Remaining in study
(n = 0)
Enrollment into this
cohort was
discontinued following
a protocol amendment

Cohort D
Extracranial solid
tumor with NTRK or
ROS1 gene fusion
Dose: 550 mg/m2
(F1) or 300 mg/m2
(F06) (n = 4)
Received entrectinib
550 mg/m2 (F1) or
300 mg/m2 (F06)
(n = 4)

Included in analysis
(n = 4)

Cohort E
Patients unable to
swallow intact
capsules
Dose: 400 mg/m2
(F1) (n = 9)
Received entrectinib
400 mg/m2 (n = 9)
Included in analysis
(n = 9)
CNS tumors (n = 5)
Extracranial tumors (n = 3)
Neuroblastoma (n = 1)

Discontinued treatment
(n = 2)

Discontinued treatment
(n = 6)

Remaining in study
(n = 4)

Adverse event (n = 1)
Other (n = 1)
Progressive disease (n = 3)
Withdrawal of consent (n = 1)

Adverse event (n = 2)

In follow-up (n = 2)
On study treatment (n = 2)

This cohort is open for
continued enrollment

Remaining in study
(n = 6)
On study treatment (n = 3)
In follow-up (n = 3)

Enrollment into this
cohort was
discontinued following
a protocol
amendment; enrolled
patients were merged
c
into cohorts B and D

Fig. 1 CONSORT diagram. aFollowing implementation of protocol version 5 (October 25, 2018), enrollment in cohorts C and E was closed; cohort
A was completed following dose-escalation recruitment. Enrollment continued in cohorts B (for patients with primary CNS tumors with gene fusions) and D (for patients with extracranial tumors with gene fusions). Following closure of cohort E, new patients that were unable to swallow
capsules were enrolled in cohorts B and D, depending on their tumor type. Molecular testing was required, prior to enrollment in cohorts B or
D. bPatients in cohorts B, C, and D received entrectinib at the MTD (F1 formulation at 550 mg/m2 or F06 formulation at 300 mg/m2), and patients
in cohort E received entrectinib at 400 mg/m2 (F1 formulation) mixed with soft foods. cPrimary CNS tumors, n = 5; extracranial solid tumors, n = 3;
neuroblastoma, n = 1. The patient with neuroblastoma was not merged into cohorts B or D; they were followed up separately. Abbreviations: CNS,
central nervous system; F1, F1 formulation; F06, F06 formulation; MTD, maximum tolerated dose; NTRK, neurotrophic tyrosine receptor kinase;
ROS1, ROS proto-oncogene 1.
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STARTRK-NG is a multicenter, non-randomized, openlabel, single-arm phase 1-2 trial of entrectinib in pediatric patients with extracranial solid tumors or primary
CNS tumors, with or without target gene fusions in
NTRK1/2/3, ROS1, or ALK (Figure 1). Patients were recruited from 34 hospitals in Canada, France, South Korea,
Spain, Taiwan, the United Kingdom, and the United States
(Supplementary Table S1).
Target gene fusions in NTRK1/2/3, ROS1, or ALK were
those predicted to translate into a fusion oncoprotein
with a functional kinase domain and without another
concomitant oncogenic driver. Target gene fusions were
identified by validated nucleic acid-based diagnostic assays performed in a Clinical Laboratory Improvement
Amendments or equivalently certified central or site laboratory. Following the implementation of protocol version 5 (October 25, 2018), for patients enrolled based on
a biomarker-eligible result from local molecular testing,
submission of an archival tumor tissue sample from
diagnosis or relapsed disease has been required for

Desai et al. Entrectinib in children and young adults

Drug Formulation and Pharmacokinetics

Outcomes

Drug formulation administration is detailed in the
Supplementary file, page 1. First dose pharmacokinetic
(PK) evaluations were performed in phase 1 and cohort E
of phase 2. PK parameters were estimated using a noncompartmental analysis (WinNonlin Certara, Princeton,
NJ, USA), and summary statistics were calculated.

The phase 1 primary objective was to determine the MTD
and the RP2D of entrectinib in pediatric patients with relapsed or refractory solid tumors. The phase 2 primary objective was to evaluate the ORR in patients with primary
CNS or extracranial solid tumors harboring NTRK1/2/3 or
ROS1 gene fusions by BICR.
Key secondary objectives were: in all patients receiving
entrectinib, safety, duration of response (DoR), time to response (TtR), clinical benefit rate, progression-free survival
(PFS), and overall survival (OS); in phase 1 and phase 2 cohort E, PK of entrectinib (all formulations) in plasma; in patients with measurable primary or secondary CNS disease
(using RANO or RANO-brain metastases, as applicable), intracranial tumor response, DoR, TtR, and CNS-PFS.

Procedures
In phase 1, patients were enrolled using a 3 + 3 design to
evaluate up to 4 entrectinib doses (250, 400, 550, 750 mg/
m2) and define the maximum tolerated dose (MTD).
Entrectinib was administered orally with food, once daily
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in 28-day cycles, and adherence to protocol therapy was
documented in a medication diary. Up to 2 dose reductions
for treatment-related adverse events (TRAEs) were permitted, prescribed by a dosing nomogram (Supplementary
Table S3). Upon completion of phase 1, phase 2 accrual
was initiated (Figure 1).
The MTD was administered to patients enrolled in phase
2 cohorts B-D. Patients in cohort E received 1 dose level
below the MTD during cycle 1 and could then escalate to
the MTD. In the absence of progressive disease (PD) or
toxicity requiring treatment discontinuation, there was no
maximum number of treatment cycles. Following protocol
amendment 5, patients able to swallow intact capsules
received the F06 entrectinib formulation; cohorts C and E
were closed, and patients in cohort E were merged into cohorts B or D (Figure 1).
Physical examinations and routine laboratory panels
were conducted weekly during cycle 1, every 2 weeks
during cycles 2-6, and at the start of each subsequent cycle.
Electrocardiograms were performed during screening, before and after the first dose on cycle 1, pre-dose on cycle
1, day 22 and day 1 of cycles 2-6, and at the end of treatment. Treatment continued until evidence of PD (and beyond if sufficient evidence of clinical benefit) or failure to
resolve a dose-limiting toxicity (DLT) to grade ≤2 or baseline within 21 days of drug discontinuation. Toxicities were
graded according to National Cancer Institute Common
Toxicity Criteria for Adverse Events (v4.03) or pediatricspecific criteria for peripheral neuropathy.19 Safety follow-up was conducted until 25-35 days following the last
entrectinib dose.
In phase 1 and phase 2 cohort E, response assessments
were performed at screening, every 2 cycles x3, every 3
cycles x2, every 4 cycles x3, then once every 6 cycles. In
phase 2 cohorts B, C, and D, response assessments were
performed at screening and every 8 weeks thereafter.
Objective response (complete response [CR] or partial response [PR]) was assessed using disease-specific criteria.
Confirmed objective responses were those confirmed by
subsequent assessment ≥28 days after initial response;
patients without either a confirmed objective response or
post-baseline tumor assessments were considered nonresponders. Blinded independent central review (BICR)
was performed for patients with a target gene fusion.

NeuroOncology

central standardized biomarker testing. Phase 1 was an
all-comer solid tumor trial, based on entrectinib being a
multitargeted kinase inhibitor.11 No responses were seen
in patients with tumors lacking target gene fusions and
therefore protocol version 6 (May 21, 2019) restricted enrollment to patients with tumors harboring NTRK1/2/3 or
ROS1 gene fusions.
Eligible patients were aged <22 years with relapsed or refractory (failed to respond to frontline curative therapy) disease and had: Lansky or Karnofsky performance score of
≥60%; life expectancy of ≥4 weeks; adequate bone marrow,
liver, renal, cardiac, and neurologic function; ability to
swallow entrectinib capsules intact (if unable they were
enrolled into phase 2, cohort E and permitted to mix the
contents [F1 formulation] with soft foods); and sufficiently
recovered from acute toxic effects of previous therapy to
meet the defined eligibility criteria (Supplementary Table
S2). Patients previously treated with TRK, ROS1, or ALK
inhibitors were only eligible for phase 1. Following protocol amendment 8 (December 17, 2019), enrollment was
restricted to patients aged <18 years and included patients
without satisfactory treatment options or where surgical
resection was likely to result in severe morbidity, including
newly diagnosed patients.
Patients were required to have measurable (or
evaluable; Supplementary file, page 1) disease at baseline
by Response Evaluation Criteria in Solid Tumors (RECIST)
v1.116 (phase 1; phase 2, cohorts C, D, and E [extracranial tumors]), Response Assessment in Neuro-Oncology
criteria17 (RANO; phase 2, cohorts B and E [primary CNS
tumors]), or evaluable disease by Curie score18 (phase 2,
cohort C [neuroblastoma with metaiodobenzylguanidine
(MIBG)-evaluable disease]). Patients were excluded if they
had active infections or were pregnant, breastfeeding,
or receiving enzyme-inducing antiepileptic medication.
Details on the different cohorts in this study are provided
in Figure 1.
The study protocol and all amendments were approved by institutional review boards at all participating
institutions. The study was conducted according to the
Declaration of Helsinki and International Council for
Harmonisation guidelines for Good Clinical Practice.
Signed informed consent and assent were obtained according to regulatory and institutional guidelines.
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Statistical Analysis

Results
Patient Characteristics
Between May 2016 and September 2020, 43 patients were
enrolled (Table 1). Phase 1 dose-escalation enrolled 16 patients, including 7 patients treated at 550 mg/m2 dose (F1
formulation) and included in phase 2. Phase 2 expansion
enrolled 27 additional patients (Figure 1). Twenty-six patients had tumors with target gene fusions (phase 1, n = 3;
phase 2, n = 23).

Phase 1 Determination of MTD
Sixteen patients were enrolled in phase 1, of whom 15
were evaluable for toxicity. One patient was non-evaluable
as they had PD and received <75% of the prescribed dose
(F1 formulation). Four patients (550 mg/m2, n = 1; 750 mg/
m2, n = 3) experienced 5 DLTs (Supplementary Table S4).

Phase 1 and Phase 2 Safety
All patients reported ≥1 adverse event (AE) (43/43; 100%)
and 76.7% experienced grade 3/4 events (Supplementary
Table S5). Dizziness (any cause; any grade) was reported
in 6 patients (14%; Supplementary Table S5). Any grade
TRAEs occurred in 97.7% (42/43) of patients and grade 3/4
events in 53.5% (Table 2). The most common TRAEs included weight gain (48.8%), anemia (39.5%), increased
blood creatinine (39.5%), and nausea (34.9%). Of the 17 patients who had increased blood creatinine, 13 (76.5%) had
a resolved event. All events were grade 1 or 2 and 7 (41.2%)
of the patients who had a reported event had more than
1 episode of blood creatinine increased. Other notable
TRAEs included neurological effects, such as somnolence
(9.3%) and paresthesia (4.7%), and bone fractures. Nine
patients (20.9%) experienced 13 bone fracture events, of
which maximum severity was grade 2 (non-operative) for
8/13 and grade 3 (operative intervention required) for 5/13
(Supplementary Table S6). Two patients with primary CNS
tumors receiving the MTD had bilateral femoral fractures
(cycle 4; cycle 8); both had rapid weight gain. Eight fracture events (61.5%) were considered related to entrectinib;
of which, 2 had not resolved at data cutoff. Eleven of the 13
(84.6%) fractures had recovered/resolved with or without
sequelae by data cutoff. These had been managed by dose
interruption or withdrawal, where necessary.
AEs led to dose reduction in 16 patients (37.2%) (weight
gain [n = 5]; increased blood creatinine [n = 2]; prolonged
corrected QT interval, ataxia, dysgeusia, headache, fatigue,
intermittent falling episodes, neutrophil count decreased,
bilateral femur fracture, and pulmonary edema [all n = 1]).
Eight patients (18.6%) discontinued entrectinib due to AEs
(fractures [n = 3]; dyspnea, encephalitis, pancreatitis, increased alanine aminotransferase, and pulmonary edema
[all n = 1]). Twenty-one patients (48.8%) experienced dose
interruptions. Across all patients, median dose intensity
was 98.8% (95% CI 78.8-100.0). Among 34 patients treated
at the MTD/RP2D (all formulations), 13 (38.2%) had an initial dose reduction due to an AE a median of 149 days after
first entrectinib dose; 7 (20.6%) required discontinuation.
No AE or TRAE led to death.

Pharmacokinetics and Dose-Finding
PK data for the F1 formulation can be found in the
Supplementary file, page 1 and Supplementary Table S7.
The dose rationale for the F1 formulation of 550 mg/m2 was
based on the MTD, but the F1 formulation was not suitable
for commercial use and was therefore discontinued.
The RP2D of 300 mg/m2 (F06 formulation) was determined by 2 modeling approaches: (1) the population
pharmacokinetic (PopPK) modeling, a top-down (semiempirical) approach,20 and (2) physiologically based
pharmacokinetic (PBPK) modeling in both Simcyp21 and
Gastroplus22 (bottom-up approach; more physiologic and
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In phase 1, patients were evaluable for toxicity and MTD
determination if they received ≥75% of the prescribed
dose, experienced a DLT, or discontinued treatment due to
toxicity during cycle 1. Patients without a DLT who discontinued treatment due to PD or reasons unrelated to toxicity
were replaced if they received <75% of the prescribed dose
during cycle 1. Using the 3 + 3 dose-escalation schema,
the MTD was defined as the dose level immediately below
that at which ≥2 patients from a cohort of 3-6 patients experienced a DLT. Sample size was based on 3 + 3 design
requirements (6-30 patients).
Phase 2 cohorts B and D utilized a 2-stage sequential
design. A minimum of 10 patients were planned for initial
enrollment in the expansion cohorts (B or D; excluding patients transferred from cohort E) and followed for at least
6 months. If ≥40% ORR (target response) was observed
at the interim efficacy analysis, approximately 10 additional patients could be further enrolled in the expansion
cohorts B or D. The efficacy endpoint for each cohort will
be considered met if ORR of ≥40% is observed following
additional expansion. Baseline characteristics and TRAE
frequencies were summarized using descriptive statistics. Safety-evaluable population comprised patients who
received any dose of entrectinib. Response-evaluable patients received ≥1 dose of entrectinib at the MTD (F1 formulation) or RP2D (F06 formulation) and had measurable/
evaluable disease at baseline. All-comer ORR was calculated for all response-evaluable patients. ORR per BICR
was the proportion of responders (PR and CR) among patients with tumors harboring target gene fusions. TtR (time
from first dose to documentation of objective response),
DoR (time from first objective response to radiographic
disease progression), and PFS were calculated using the
Kaplan-Meier method.
Following protocol amendment 5, interim analyses of
efficacy data were specified following enrollment of ≥10
patients and completion of 6-month follow-up for each cohort. Data cutoff for this analysis was September 17, 2020.

DLTs were reversible following dose reduction (dysgeusia
and pulmonary edema) and/or interruption (increased creatinine). Daily entrectinib 550 mg/m2 (F1 formulation) was
established as the MTD in pediatric patients.
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   Salivary gland adenocarcinoma

Extracranial solid tumor

0

0

0

0

1 (33.3)

3 (100.0)

3 (100.0)

2 (66.7)

2 (66.7)

3 (100.0)

1 (33.3)

550 mg/m

0

0

2 (28.6)

0

2 (28.6)

5 (71.4)

2 (28.6)

1 (14.3)

4 (57.1)

5 (71.4)

1 (16.7)

4 (66.7)

0

1 (16.7)

0

1 (14.3)

0

6 (85.7)

0

0

1 (14.3)

6 (85.7)

2 (28.6)

5 (71.4)

7 (6-17)

(n = 7)

2

750 mg/m

0

0

0

1 (33.3)

1 (33.3)

2 (66.7)

3 (100.0)

0

1 (33.3)

3 (100.0)

0

2 (66.7)

1 (33.3)

0

0

0

1 (33.3)

2 (66.7)

0

0

0

3 (100.0)

1 (33.3)

2 (66.7)

10 (4-16)

(n = 3)

2

0

1 (3.7)

3 (11.1)

1 (3.7)

7 (25.9)

11 (40.7)

4 (14.8)

0

4 (14.8)

19 (70.4)

10 (37.0)

6 (22.2)

8 (29.6)

1 (3.7)

2 (7.4)

1 (3.7)

0

23 (85.2)

3 (11.1)

1 (3.7)

2 (7.4)

24 (88.9)

15 (55.6)

12 (44.4)

5 (2 months-19 years)a

(n = 27)

Phase 2

1 (2.3)

1 (2.3)

5 (11.6)

2 (4.7)

12 (27.9)

24 (55.8)

12 (27.9)

3 (7.0)

11 (25.6)

33 (76.7)

15 (35.7)

13 (31.0)

10 (23.8)

2 (4.8)

2 (4.8)

2 (4.7)

1 (2.3)

36 (83.7)

4 (9.3)

1 (2.3)

5 (11.6)

37 (86.0)

21 (48.8)

22 (51.2)

7 (2 months-20 years)

(n = 43)

All Patients
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  Infantile fibrosarcoma

1 (33.3)

0

Immunotherapy

Tumor type/histology, n (%)

3 (100.0)

Chemotherapy

Prior systemic therapies, n (%)

100

1 (33.3)

0

70

0

0

60

0

2 (66.7)

0

1 (33.3)

0

1 (33.3)

2 (66.7)

2 (66.7)

1 (33.3)

15 (6-20)

Non-Hispanic or Latino

Karnofsky/Lansky score, n (%)b

2

400 mg/m
(n = 3)

Hispanic or Latino

Ethnicity, n (%)

2 (66.7)

White

Race, n (%)

2 (66.7)

Female

9 (7-13)

(n = 3)

250 mg/m

Male

Sex, n (%)

Median age, years (range)

Characteristic
2

Phase 1 Dose-Escalation (n = 16)

NeuroOncology

  
Table 1. Patient Demographic and Baseline Characteristics
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0
0
0
0
0
0

  Ganglioglioma

   Epithelioid glial neoplasm

  Medulloblastoma

   High-grade glioma NOS

  Glioma NOS

  Ganglioneuroblastoma

0

0
0

ROS1

ALK

0
0

ROS1

ALK

0

0

1 (33.3)

0

0

2 (28.6)

1 (14.3)

1 (14.3)

1 (14.3)

0

1 (14.3)d

1 (14.3)

1 (14.3)

0

5 (71.4)

0

0

0

0

0

0

0

0

0

0

0

0

(n = 7)

550 mg/m2

0

0

1 (33.3)

0

0

0

0

0

1 (33.3)

2 (66.7)

0

0

0

0

0

0

0

0

0

0

0

0

(n = 3)

750 mg/m2

3 (11.1)

7 (25.9)

14 (51.9)

1 (3.7)

0

0

2 (7.4)

7 (25.9)

14 (51.9)

4 (14.8)

1 (3.7)

1 (3.7)

3 (11.1)

1 (3.7)

1 (3.7)

2 (7.4)

4 (14.8)

3 (11.1)

16 (59.3)

1 (3.7)

1 (3.7)

0

(n = 27)

Phase 2

5 (11.6)

8 (18.6)

17 (39.5)

2 (4.7)

0

2 (4.7)

3 (7.0)

8 (18.6)

15 (34.9)

15 (34.9)

1 (2.3)

1 (2.3)

3 (7.0)

1 (3.7)

1 (2.3)

2 (4.7)

4 (9.3)

3 (7.0)

16 (37.2)

1 (2.3)

1 (2.3)

1 (2.3)

(n = 43)

All Patients
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Abbreviations: ALK, anaplastic lymphoma kinase; CNS, central nervous system; IMT, inflammatory myofibroblastic tumor; NTRK, neurotrophic tyrosine receptor kinase; NOS, not otherwise specified; ROS1,
ROS proto-oncogene 1.
aPatient aged 2 months received 250 mg/m2 dosage.
bn = 42; 1 patient in 550 mg/m2 dose group was excluded from Karnofsky/Lansky score category due to incorrect performance score scale for age.
cNo non-fusion gene alterations were identified in NTRK2 or 3.
dConsidered variants of unknown significance.

0

NTRK1/2/3

Any target gene alteration, n (%)

0

NTRK1c

Non-fusion target gene alteration, n (%)
1 (33.3)d

0

0

ALK

0

0

ROS1

0

2 (66.7)

0

0

0

0

0

0

0

0

0

0

0

NTRK1/2/3

Target gene fusion, n (%)

2 (66.7)

0

  Astrocytoma

Neuroblastoma

0

  Glioblastoma

0

0

  Infantile myofibroma

Primary CNS (brain) tumor

0

  Myofibroblastic tumor

(n = 3)
1 (33.3)

(n = 3)
0

400 mg/m2

250 mg/m2

Phase 1 Dose-Escalation (n = 16)

   Spindle cell sarcoma

Characteristic

  
Table 1. Continued
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0
0

1 (33.3)

2 (66.7)

3 (100)

1 (33.3)

0

2 (66.7)

0

0

0

0

0

1 (33.3)

0

0

1 (33.3)

0

0

0

1 (33.3)

0

0

0

0

0

0

0

0

0

0

0

0

Anemia

Blood creatinine increased

Nausea

Constipation

ALT increased

AST increased

Neutrophil count decreased

White blood cell decreased

Vomiting

Diarrhea

Dysgeusia

Fatigue

Flatulence

Urinary incontinence

Hypernatremia

Fracture (combined)a

Headache

Abdominal pain

Pain in extremity

Increased appetite

Platelet count decreased

Neutropenia

Lymphocyte count decreased

Dyspnea

Syncope

Neutrophil percentage decreased

Pancreatitis

Pulmonary edema

Pneumonia

Respiratory failure

Hypoxia

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1 (33.3)

1 (33.3)

0

0

0

2 (66.7)

1 (33.3)

0

1 (33.3)

2 (66.7)

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1 (33.3)

0

0

0

0

0

0

0

1 (33.3)

G3/4

0

0

0

0

0

0

0

0

0

0

0

0

1 (14.3)

2 (28.6)

1 (14.3)

1 (14.3)

0

1 (14.3)

2 (28.6)

0

2 (28.6)

2 (28.6)

2 (28.6)

0

1 (14.3)

1 (14.3)

3 (42.9)

4 (57.1)

2 (28.6)

2 (28.6)

2 (28.6)

4 (57.1)

7 (100)

G1/2

550 (n = 7)

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

G3/4

0

0

0

0

0

0

1 (33.3)

0

1 (33.3)

0

1 (33.3)

0

0

0

1 (33.3)

0

1 (33.3)

1 (33.3)

2 (66.7)

1 (33.3)

2 (66.7)

0

0

2 (66.7)

0

2 (66.7)

2 (66.7)

1 (33.3)

1 (33.3)

2 (66.7)

2 (66.7)

1 (33.3)

1 (33.3)

G1/2

750 (n = 3)

1 (33.3)

1 (33.3)

1 (33.3)

1 (33.3)

0

0

0

1 (33.3)

0

0

1 (33.3)

0

0

0

0

0

0

0

0

0

0

0

0

0

1 (33.3)

0

0

0

0

0

0

0

2 (66.7)

G3/4

0

0

0

0

0

0

0

1 (3.7)

1 (3.7)

1 (3.7)

2 (7.4)

5 (18.5)

3 (11.1)

3 (11.1)

3 (11.1)

3 (11.1)

4 (14.8)

5 (18.5)

3 (11.1)

5 (18.5)

3 (11.1)

5 (18.5)

7 (25.9)

5 (18.5)

2 (7.4)

3 (11.1)

4 (14.8)

7 (25.9)

8 (29.6)

9 (33.3)

11 (40.7)

9 (33.3)

6 (22.2)

G1/2

0

0

0

0

1 (3.7)

1 (3.7)

1 (3.7)

0

1 (3.7)

3 (11.1)

0

0

0

0

0

2 (7.4)

0

0

0

1 (3.7)

0

0

0

2 (7.4)

5 (18.5)

1 (3.7)

2 (7.4)

0

0

0

1 (3.7)

7 (25.9)

20 (74.1)

G3/4

Phase 2 (n = 27)

0

0

0

0

0

0

1 (2.3)

1 (2.3)

2 (4.7)

1 (2.3)

3 (7.0)

5 (11.6)

5 (11.6)

5 (11.6)

5 (11.6)

4 (9.3)

6 (14.0)

7 (16.3)

7 (16.3)

7 (16.3)

8 (18.6)

8 (18.6)

9 (20.9)

7 (16.3)

3 (7.0)

10 (23.3)

10 (23.3)

13 (30.2)

15 (34.9)

17 (39.5)

16 (37.2)

14 (32.6)

19 (44.2)

G1/2

Total (n = 43)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

3 (7.0)

1 (2.3)

0

0

0

0

2 (4.7)

0

0

0

1 (2.3)

0

0

0

2 (4.7)

7 (16.3)

1 (2.3)

2 (4.7)

0

0

0

1 (2.3)

7 (16.3)

23 (53.5)

G3/4

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

1 (2.3)

2 (4.7)

2 (4.7)

3 (7.0)

4 (9.3)

4 (9.3)

5 (11.6)

5 (11.6)

5 (11.6)

5 (11.6)

6 (14.0)a

6 (14.0)

7 (16.3)

7 (16.3)

8 (18.6)

8 (18.6)

8 (18.6)

9 (20.9)

9 (20.9)

10 (23.3)

11 (25.6)

12 (27.9)

13 (30.2)

15 (34.9)

17 (39.5)

17 (39.5)

21 (48.8)

42 (97.7)

Any G
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Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRAE, treatment-related adverse event.
AEs were encoded using Medical Dictionary for Regulatory Activities (version 21.0).
Values for the total population (Phase 1 and Phase 2) are shown in bold for emphasis.
aIncludes preferred terms fibula fracture, femur fracture, fracture, tibia fracture, pathological fracture, and stress fracture. Values correspond to the number (%) of patients, not events. See Supplementary Table
S6 for all fracture events (all causality).

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Weight gain

2 (66.7)

G1/2

0

G3/4

3 (100)

G1/2

Any TRAE

400 (n = 3)

250 (n = 3)

Phase 1 Dose Escalation, mg/m2 (n = 16)

  
Table 2. Summary of the Most Common Grade 1/2 Treatment-Related Adverse Events During Phases 1 and 2 (>10% Incidence in Total Safety-Evaluable Population) and Any Grade 3/4 Treatment-Related
Adverse Events (All Treatment Cycles)
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Phase 1 and Phase 2 Efficacy
As of September 17, 2020, 43 patients were enrolled and
evaluated for response and 11 patients remained on treatment. For all-comer efficacy, refer to Supplementary file,
page 1.

Efficacy in CNS tumors.—In phase 2, 16 patients with primary
CNS tumors and target gene fusions were response-evaluable
(cohort B, n = 11; cohort E, n = 5; Supplementary Table S8).
Confirmed objective responses by BICR were observed in 8
patients ([4 CRs; 4 PRs]; ORR, 50.0%; 95% CI 24.7-75.4; Figure
2; Table 3). Patients in cohort B (phase 2; n = 11) showed an
ORR per BICR of 54.5% (n = 6/11; 95% CI 23.4-83.3), which met
the threshold of 40% for the interim efficacy analysis.
Figure 3A presents responses in selected patients
with primary CNS tumors and target gene fusions. One
patient who did not respond at first disease evaluation
on therapy enrolled with a relapsed medulloblastoma
harboring a purported PARP6-NTRK3 fusion was noted
as out-of-frame. A patient who achieved confirmed response was an infant diagnosed aged 2 weeks with a
large pontine tumor (a presumed fatal diffuse intrinsic
pontine glioma); subsequent diagnostic tumor biopsy revealed an ETV6-NTRK3 fusion. Entrectinib treatment was
initiated aged 2 months and resulted in a CR; the patient
remains on therapy after 1 year (Figure 3B). In total, 7/16
patients remain on treatment; 9 discontinued treatment
due to PD (n = 6) or an AE (n = 3; bone fracture, tibia fracture, or pancreatitis [all n = 1]).
Efficacy in extracranial solid tumors.—Ten patients en-

Efficacy according to the presence or absence of target
gene fusion.—The target fusion population (n = 26) comprised 16 patients with primary CNS tumors and 10 with
extracranial solid tumors; confirmed ORR was 57.7%
(15/26; 95% CI 36.9-76.7), including 7 CRs (26.9%) and 8
PRs (30.8%; Table 3). In the non-fusion population (n = 17),
1 patient with neuroblastoma harboring an ALK F1174L
point mutation achieved a CR (investigator-assessed Curie
score); investigator-assessed ORR was 5.9% (1/17; 95% CI
0.15-28.7; Supplementary Figure S3).
In the target fusion population, reductions in measurable
target lesions were observed in 17/21 (80.9%) patients; 2
patients did not meet the definition of confirmed objective
response at the time of data cutoff, as they were not measured on 2 separate evaluations >4 weeks apart) (Figure 2A).
Of the 15 confirmed objective responses (BICR-assessed),
14 (93.3%) were observed at the first evaluation (end
of cycle 2; Figure 2B). Median DoR (95% CI) among responders in the target fusion population (BICR-assessed)
was not reached (14.3 months-not evaluable [NE]), due to
patients still receiving therapy. Median duration of treatment (interquartile range) at data cutoff was 10.6 months
(4.2-18.4) in the target fusion population and 1.8 months
(1.7-2.1) in the non-fusion population. Median PFS (95% CI)
was not reached (12.8 months-NE) in the target fusion population and 1.9 months (1.7-5.7) in the non-fusion population (P < .0001; Supplementary Figure S4).

Efficacy according to type of target gene fusion.—The
target fusion population (n = 26) comprised 15 patients
with NTRK1/2/3 fusions, 8 patients with ROS1 fusions, and
3 patients with ALK fusions. Confirmed ORR was 60.0%
(9/15; 95% CI 32.3-83.7), 62.5% (5/8; 95% CI 24.5-91.5), and
33.3% (1/3; 95% CI 0.84-90.6) in patients with NTRK1/2/3,
ROS1, and ALK fusions, respectively (Table 3).

rolled with extracranial solid tumors and target gene fusions were evaluable for response (Supplementary Table
S9); 3 were enrolled in phase 1 (550 mg/m2, n = 2; 750 mg/
m2, n = 1) and 7 in phase 2 (cohort D, n = 4; cohort E, n = 3).
Confirmed objective responses were observed in 7 patients ([3 CRs; 4 PRs]; 70.0%; 95% CI 34.8-93.3; Figure 2;
Table 3). ORR for cohort D (phase 2) alone could not be calculated yet, as only 4 patients had been enrolled in this cohort at the data cutoff. Per the protocol, ORR for the interim
analysis will be evaluated when another 6 patients have
been enrolled in this cohort.
Figure 3C presents responses in selected patients with
extracranial solid tumors and target gene fusions. Three
patients remain on treatment; 7 discontinued due to AEs
(n = 3; femur fracture, increased alanine and aspartate
aminotransferase, or pulmonary edema [all n = 1]) study
withdrawal (n = 2), persistent toxicities (n = 1), and prolonged non-evaluable disease status (n = 1).
Fifteen patients with neuroblastoma were evaluable for
response (phase 1, n = 11; phase 2, n = 4). One patient with
neuroblastoma harboring an ALK point mutation (F1174L)
had a CR by Curie score (Supplementary Figure S3), and
3 patients had stable MIBG-evaluable disease by Curie
score, and 8 patients had PD. Three patients had missing
data/unevaluable responses.

Discussion
In this phase 1/2 study, entrectinib showed a positive
benefit-risk profile in pediatric patients with solid tumors,
including CNS tumors, harboring target NTRK1/2/3 or
ROS1 fusions. Frequent TRAEs were grade 1 or 2 weight
gain, anemia, or gastrointestinal side effects, including
nausea or constipation. In phase 1, reversible grade 3
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considering organ maturation). These models consistently
predicted similar entrectinib PK exposures in pediatric and
adult patients with a recommended dose of 300 mg/m2.
Individual PK estimates were calculated using the PopPK
model for all available pediatric patients dosed with the
F1 formulation. These individual values were used to estimate what systemic exposures would have been achieved
if the patients had been given the 300 mg/m2 dose with
the F06 formulation (Supplementary Figure S1A). The data
show that systemic exposure across all pediatric ages
with the F06 formulation is within the efficacious and tolerable range that has been established in the adult population (Supplementary Figure S1B). Supplementary Figure
S2 shows PK data from the first pediatric patient dosed
with 300 mg/m2 at the F06 formulation; the systemic exposure of this patient was well within the range of the adult
exposure.
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*

100

NTRK fusion
ALK fusion
ROS1 fusion
* Fusion not in-frame
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50

CR
PR
SD
PD

25
0
–25
–50
–75

DCTN1-ALK; IMT
ETV6-NTRK3; Melanoma
ETV6-NTRK3; Epithelioid glioblastoma
GOPC-ROS1; Diffuse midline glioma, H3 K27M-mutant
ARHGEF2-NTRK1; Glioblastoma
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ETV6-NTRK3; Astrocytoma
TFG-ROS1; IMT
EML4-NTRK3; Infantile fibrosarcoma
EML1-NTRK2; Anaplastic ganglioglioma
EEF1G-ROS1; Desmoplastic infantile astrocytoma with anaplastic features
FN1-ROS1; IMT
KANK1-NTRK2; Ganglioneuroblastoma of the CNS
TPM3-NTRK1; Infantile myofibroma
GOPC-ROS1; Glioma NOS
ETV6-NTRK3; Biphasic and spindled epithelioid glial neoplasm
TFG-ROS1; IMT
KIF5B-ALK; IMT
GOPC-ROS1; Pilocytic astrocytoma
TFG-ROS1; Myofibroblastic tumor
BCR-NTRK2; Ganglioglioma
EML4-ALK; HGG NOS
*PARP6-NTRK3; Nodular desmoplastic medulloblastoma

TPR-NTRK1; HGG NOS

ETV6-NTRK3; Infantile fibrosarcoma

ETV6-NTRK3; Melanoma
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TFG-ROS1; IMT

GOPC-ROS1; Glioma NOS

TPM3-NTRK1; Infantile myofibroma

B

EEF1G-ROS1; Desmoplastic infantile astrocytoma with anaplastic features

KIF5B-ALK; IMT

TFG-ROS1; Myofibroblastic tumor

TFG-ROS1; IMT

GOPC-ROS1; Pilocytic astrocytoma
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PARP6-NTRK3; Nodular desmoplastic medulloblastoma
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Still on treatment
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First PD
First CR/PR
* Fusion not in-frame
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Fig. 2 Responses to entrectinib as assessed by BICR in patients with tumors harboring target gene fusions (n = 26). (A) Waterfall plot of BICRassessed maximum percentage change in tumor size from baseline as measured by RECIST or RANO in patients with measurable target lesions.
Plot includes 21 patients with both baseline and post-baseline measurements available for SLD or SPD. Five patients were excluded due to the
presence of non-target lesions only (n = 3) or non-evaluable response (n = 2). Best overall confirmed responses per BICR assessment are also
indicated; note that confirmed response does not align with best percentage improvement from baseline in SLD/SPD in 5 patients due to consideration of response in non-target lesions (n = 2), development of new lesions (n = 1), and requirement for confirmation of response after ≥28 days
(n = 2; initial PR unconfirmed due to subsequent surgical resection [n = 1] or new lesion [n = 1]). (B) Swimmer plot of BICR-assessed best overall
response from start of therapy to time of last therapy. Abbreviations: ALK, anaplastic lymphoma kinase; BICR, blinded independent central review; CNS, central nervous system; CR, complete response; HGG, high-grade glioma; IMT, inflammatory myofibroblastic tumors; NOS, not otherwise specified; NTRK, neurotrophic tyrosine receptor kinase; PD, progressive disease; PR, partial response; RANO, Response Assessment in
Neuro-Oncology; RECIST, Response Evaluation Criteria in Solid Tumors; ROS1, ROS proto-oncogene 1; SD, stable disease; SLD, sum of longest
diameter; SPD, sum of products of diameters.
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Table 3. Summary of BICR-Assessed Best Overall Confirmed Responses in Patients With Tumors Harboring Target Gene Fusions, According to
Fusion Kinase and Tumor Type
Response, n (%)

Tumor Type

Total (n = 26)

NTRK1/2/3
(n = 15)

ROS1
(n = 8)

ALK
(n = 3)

Primary CNS
(n = 16)

Extracranial Solid
(n = 10)

60.0 (32.3, 83.7)

62.5 (24.5, 91.5)

33.3 (0.84, 90.6)

50.0 (24.7, 75.4)

70.0 (34.8, 93.3)

57.7 (36.9, 76.7)

Complete response

5 (33.3)

1 (12.5)

1 (33.3)

4 (25.0)

3 (30.0)

7 (26.9)

Partial response

4 (26.7)

4 (50.0)

0

4 (25.0)

4 (40.0)

8 (30.8)

Stable disease

4 (26.7)

2 (25.0)

1 (33.3)

5 (31.3)

2 (20.0)

7 (26.9)

Progressive disease

1 (6.7)

0

1 (33.3)

2 (12.5)

0

2 (7.7)

Missing/unevaluable

1 (6.7)

1 (12.5)

0

1 (6.3)

1 (10.0)

2 (7.7)

Abbreviations: ALK, anaplastic lymphoma kinase; BICR, blinded independent central review; CI, confidence interval; CNS, central nervous
system; CR, complete response; NTRK, neurotrophic tyrosine receptor kinase; PD, progressive disease; ROS1, ROS proto-oncogene 1.

  
pulmonary edema and persistent grade 2 increased creatinine, fatigue, and dysgeusia were DLTs that established 550 mg/m2 (F1 formulation) as the MTD. In phase 2,
TRAEs were similar to those reported in adults,1 and consistent with the on-target effects of entrectinib. Dysgeusia
and ataxia may be related to the role of TRKA or TRKC in
proprioception and sensation.5 Weight gain, possibly associated with TRKB-mediated effects on appetite, and
neurocognitive side effects have been reported with other
ALK/ROS1 inhibitors.23 For patients with weight gain, dietary modifications and counseling are recommended. To
assess the effects of entrectinib on cognitive development
in children, the neurocognitive examination was incorporated into the safety assessment schedule following protocol amendment 8.
Nine patients experienced 13 bone fracture events,
of which 8 were considered related to entrectinib and 11
had recovered/resolved at data cutoff. An association between fractures and TRK inhibitors has not yet been established; however, neurotrophins and TRK receptors may be
involved in bone formation and healing.24 No gender, histology type, tumor location, or gene fusion patterns have
been observed to date to be associated with a higher incidence of fractures. Protocol amendments have implemented close monitoring and biomarker measurement
(bone mineral density and markers of bone formation,
resorption, and calcium metabolism) to increase understanding of fracture etiology and risk.
Exposure to entrectinib (F1 formulation) increased with
dose but was highly variable, due to F1 formulation sensitivity to gastric conditions.22 Three patients received a different formulation (F2B), adding to the observed variability.
Overall, systemic exposure in some pediatric patients receiving the F1 formulation was lower than that seen in
adults receiving the 600 mg dose (F06 formulation), due to
the sensitivity of the F1 formulation to gastric environmental
conditions.22,25,26 Pediatric patients in this trial experienced a
high frequency of TRAEs (grade 3/4, 53.5%), resulting in discontinuation in 14.0% of patients; however, median dose
intensity was high (98.8%). The MTD of 550 mg/m2 (F1 formulation) was superseded by the RP2D of 300 mg/m2 (F06
formulation) based on PK modeling approaches.20,21 Ongoing

studies will evaluate the safety and efficacy of the F06 formulation (300 mg/m2), and a pediatric age-appropriate formulation (minitablets) in patients unable to swallow intact
capsules.25,26
Entrectinib is efficacious against solid tumors with
NTRK1/2/3 and ROS1 gene fusions. Responses occurred in patients with tumors harboring target gene
fusions irrespective of histology or location (intracranial or extracranial). Responses similar to those observed with larotrectinib (TRK inhibitor) were achieved
in patients with IF and metastatic melanoma.27 Patients
with ROS1 or ALK fusion-positive IMTs and a patient
with neuroblastoma harboring an ALK point mutation
(F1174L) showed responses, demonstrating the multitarget inhibition profile of entrectinib. A patient with
an unresectable extracranial solid tumor (IMT) at enrollment underwent complete surgical resection after a
PR with entrectinib, reflecting the potential application
of entrectinib early in the disease course. Patients with
neuroblastoma were included without biomarker selection based on preclinical data,28 likely contributing to the
limited response in this population.
Eight patients with primary CNS tumors and target
fusions achieved objective responses with entrectinib.
These patients ranged in age from 2 months to 9 years
with a variety of tumor histologies, which was expected
as pediatric gliomas present in very young children and
histologic classification is challenging.6,29 Infant HGGs
are poorly understood and often fatal in the event of
relapse.30 Rapid objective responses in this population
indicate that entrectinib treatment before surgical excision may reduce morbidity and spare or delay cranial
radiation in very young children. As demonstrated by
the infant with brainstem glioma enrolled in this trial,
molecular testing may facilitate access to entrectinib
treatment for patients where target gene fusions are not
suspected.31,32
In conclusion, entrectinib demonstrated rapid and durable activity against pediatric intracranial and extracranial solid tumors with target gene fusions in NTRK1/2/3
or ROS1. Although tumors that harbor these fusions
remain rare, the profound effect of this single agent on

Downloaded from https://academic.oup.com/neuro-oncology/article/24/10/1776/6565645 by Washington University in St. Louis user on 23 November 2022

Objective response
rate, % (95% CI)

Fusion Kinase

Desai et al. Entrectinib in children and young adults

NeuroOncology

  

A
EML1NTRK2
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After 9 cycles
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After 6 cycles

Baseline

After 2 cycles

After 8 cycles

Baseline

After 2 cycles

After 6 cycles

ETV6NTRK3

Baseline

After 2 cycles

After 6 cycles

TPRNTRK1

ETV6NTRK3

Baseline

B

Baseline

After 2 cycles

Baseline (2 months old)

After 10 cycles

After 2 cycles

After 13 cycles

C
Melanoma
ETV6-NTRK3
Baseline

After 2 cycles

Best response

Baseline

After 2 cycles

Best response

Baseline

After 2 cycles

Best response

Infantile
fibrosarcoma
EML4-NTRK3

IMT
TFG-ROS1

Fig. 3 Example MRI scans showing measurable and durable responses to entrectinib. (A) Primary CNS tumors. (B) An infant with a primary CNS
tumor determined to be an anaplastic astrocytoma harboring an ETV6-NTRK3 fusion. Patient remains on treatment after 1 year. (C) Extracranial
solid tumors. Per protocol, entrectinib was administered in 28-day cycles. Abbreviations: CNS, central nervous system; IMT, inflammatory
myofibroblastic tumor; MRI, magnetic resonance imaging; NTRK, neurotrophic tyrosine receptor kinase; ROS1, ROS proto-oncogene 1.
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these pediatric patients with life-threatening diseases
makes it invaluable to this population. Further studies
are ongoing to assess an age-appropriate formulation,
determine the optimal treatment duration, and monitor
for resistance and long-term side effects in pediatric
patients.
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